Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenny Chien

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Pharmaceutical Sciences|November 5, 2013
Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancersRodney J Y Ho, Jenny Chien
Clinical Pharmacology and Therapeutics|September 13, 2021
Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 InfectionEmmanuel Chigutsa, Lisa O'Brien, Lisa Ferguson-Sells, et al.
Journal of Diabetes Science and Technology|January 9, 2013
An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristicsMary Jane Geiger, Zachary Skrivanek, Brenda Gaydos, et al.
Journal of Diabetes Science and Technology|January 9, 2013
Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulationsZachary Skrivanek, Scott Berry, Don Berry, et al.
The Lancet. Diabetes & Endocrinology|February 9, 2023
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 studyJuan Frias, Jenny Chien, Qianyi Zhang, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 16, 2024
Understanding the Pharmacokinetics and Glucodynamics of Once Weekly Basal Insulins to Inform Dosing Principles: An Introduction to CliniciansThomas R Pieber, Jennifer Leohr, Juliana M Bue-Valleskey, et al.
Diabetes, Obesity & Metabolism|December 21, 2022
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetesTim Heise, Jenny Chien, John M Beals, et al.
Leukemia|December 6, 2019
Unexpected variation in leukemia stem cell frequency and genetic heterogeneity in two murine leukemia models initiated by AML1/ETO9a and CALM/AF10Rhea Desai, Sarvenaz Taghavi, Jessica C Chase, et al.
Diabetes Care|March 15, 2023
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 DiabetesChristof M Kazda, Juliana M Bue-Valleskey, Jenny Chien, et al.
Diabetes Care|March 21, 2023
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control TrialJuliana M Bue-Valleskey, Christof M Kazda, Chenchen Ma, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Pharmaceutical Sciences|November 5, 2013
Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancersRodney J Y Ho, Jenny Chien
Clinical Pharmacology and Therapeutics|September 13, 2021
Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 InfectionEmmanuel Chigutsa, Lisa O'Brien, Lisa Ferguson-Sells, et al.
Journal of Diabetes Science and Technology|January 9, 2013
An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristicsMary Jane Geiger, Zachary Skrivanek, Brenda Gaydos, et al.
Journal of Diabetes Science and Technology|January 9, 2013
Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulationsZachary Skrivanek, Scott Berry, Don Berry, et al.
The Lancet. Diabetes & Endocrinology|February 9, 2023
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 studyJuan Frias, Jenny Chien, Qianyi Zhang, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 16, 2024
Understanding the Pharmacokinetics and Glucodynamics of Once Weekly Basal Insulins to Inform Dosing Principles: An Introduction to CliniciansThomas R Pieber, Jennifer Leohr, Juliana M Bue-Valleskey, et al.
Diabetes, Obesity & Metabolism|December 21, 2022
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetesTim Heise, Jenny Chien, John M Beals, et al.
Leukemia|December 6, 2019
Unexpected variation in leukemia stem cell frequency and genetic heterogeneity in two murine leukemia models initiated by AML1/ETO9a and CALM/AF10Rhea Desai, Sarvenaz Taghavi, Jessica C Chase, et al.
Diabetes Care|March 15, 2023
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 DiabetesChristof M Kazda, Juliana M Bue-Valleskey, Jenny Chien, et al.
Diabetes Care|March 21, 2023
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control TrialJuliana M Bue-Valleskey, Christof M Kazda, Chenchen Ma, et al.
Pageof 2